晚期肝细胞癌治疗格局变化与生存改善相关:一项全国性人群研究
该研究基于德国InGef全国代表性索赔数据库,筛选2015至2020年肝细胞癌病例,比较仅索拉非尼时代(A期)与仑伐替尼等新系统治疗获批后(B期)的生存与费用。共识别2876例患者,接受系统治疗比例从2015年11.8%升至2020年15.1%(p<0.0001);B期中位总生存6.5个月(95%CI 4.9-8.9)vs A期5.3个月(95%CI 4.5-6.3;p=0.046)。
要点
- 接受系统治疗比例从2015年11.8%升至2020年15.1%(p<0.0001)。
- B期中位总生存6.5个月(95%CI 4.9-8.9)vs A期5.3个月(95%CI 4.5-6.3;p=0.046)。
- B期中仑伐替尼中位总生存9.7个月(95%CI 6.3-18.4)vs 索拉非尼4.8个月(95%CI 4.0-7.1;p=0.008)。
核心结论
- 新系统治疗的获批为肝细胞癌患者带来生存获益,但效应幅度中等,且伴随医疗费用的适度增加。
研究设计与样本
- 全国性代表性索赔数据库(InGef)筛查2015年至2020年肝细胞癌病例,共识别2876例。
- 比较仅索拉非尼时代(A期,2015年1月至2018年7月)与仑伐替尼及其他系统治疗获批后(B期,2018年8月至2020年12月)的生存,并评估医疗费用。
主要发现
- 接受系统治疗的患者比例从2015年11.8%上升至2020年15.1%(p<0.0001)。
- B期中位总生存为6.5个月(95%CI 4.9-8.9),A期为5.3个月(95%CI 4.5-6.3;p=0.046)。
- B期中仑伐替尼中位总生存为9.7个月(95%CI 6.3-18.4),索拉非尼为4.8个月(95%CI 4.0-7.1;p=0.008)。
- 每例患者处方药费用从2015年6150欧元增至2020年9049欧元(p<0.0001),门诊诊疗费用从1646欧元增至2149欧元(p=0.0240)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The treatment of hepatocellular carcinoma (HCC) is undergoing a historic transformation with the approval of several new systemic therapies in the last few years. This study aimed to examine the impact of this changing landscape on survival and costs in a Western nationwide, real-world cohort. METHODS: A nationwide representative claims database (InGef) was screened for HCC cases between 2015 and 2020. Survival in an era with only sorafenib (period A, January 2015 to July 2018) and after approval of lenvatinib and other systemic treatments (period B, August 2018 to December 2020) was analysed. Health care costs were assessed. RESULTS: We identified 2876 individuals with HCC in the study period. The proportion of patients receiving systemic therapy increased significantly over time, from 11.8% in 2015 to 15.1% in 2020 (p < 0.0001). The median overall survival in period B was 6.5 months (95% confidence interval [CI]: 4.9-8.9) and in period A was 5.3 months (95% CI: 4.5-6.3; p = 0.046). In period B, the median overall survival with lenvatinib was 9.7 months (95% CI: 6.3-18.4) versus 4.8 months with sorafenib (95% CI: 4.0-7.1, p = 0.008). Costs for prescription drugs per patient increased from €6150 in 2015 to €9049 in 2020 (p < 0.0001), and costs for outpatient care per patient increased from €1646 to €2149 (p = 0.0240). CONCLUSION: The approval of new systemic therapies resulted in a survival benefit in patients with HCC. The magnitude of the effect is modest and associated with a moderate increase in health costs.
引用
- Ben Khaled N, Mörtl B, Beier D, et al. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study. Eur J Cancer. 2023. PMID: 37672814. doi:10.1016/j.ejca.2023.113248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。